In this study, lipid profile was assessed, and the intimal wall thickness of both carotid arteries in children with idiopathic epilepsy was measured. The study comprised 22 children with idiopathic epilepsy on either carbamazepine or valproate. A profile including triglycerides, total cholesterol, low-density and high-density lipoproteins cholesterol, apolipoproteins AI and B, and Duplex estimation of intimal wall thickness of carotid arteries were performed. Patients on carbamazepine showed increase in total cholesterol, low-density and high-density lipoproteins cholesterol, and decrease in apolipoprotein AI levels compared with controls. Levels of total cholesterol, low-density lipoproteins cholesterol, and apolipoprotein AI were reduced in patients receiving valproate compared with controls, whereas total cholesterol, high-density lipoproteins cholesterol, and apolipoprotein AI were reduced compared with those receiving carbamazepine. Carotid arteries intimal wall thickness was not significantly changed in any of the studied groups. Although atherogenic ratios are not changed, the lowered apolipoprotein AI levels may suggest an increased risk for coronary heart disease.
Matsuda I., Higashi A., Inotsume N.Physiologic and metabolic aspects of anticonvulsants. Pediatr Clin North Am. 1989;36: 1099-1111.
2.
Pelkonen R., Fogelholm R., Nikkila EAIncrease in serum cholesterol during phenytoin treatment. Br Med J. 1975;4:85.
3.
Nikkilä EA, Kaste M., Ehnholm C., Viikari J.Increase of serum high density lipoprotein in phenytoin users. Br Med J. 1978;2:99.
4.
Durrington PNEffect of phenobarbitone on plasma apolipoprotein B and plasma high-density-lipoprotein cholesterol in normal subjects. Clin Sci. 1979;56:501-504.
5.
Luoma PV, Reunanen MI, Sotaniemi EAChanges in serum triglycerides and cholesterol levels during long term phenytoin treatment for epilepsy. Acta Med Scand. 1979 ;206:229-231.
6.
Brown DW, Ketter TA, Crumlish J., Post RMCarbamazepine-induced increase in total serum cholesterol: clinical and theoretical implications. J Clin Psychopharmacol. 1992 ;12:431-437.
7.
Isojärvi JI, Pakarinen AJ, Myllyla VVSerum lipid levels during carbamazepine medication. Arch Neurol . 1993;50:590-593.
8.
Sudhop T., Bauer J., Elger CE, Von Bergmann K.Increased high-density lipoprotein cholesterol in patients with epilepsy treated with carbamazepine: a gender-related study. Epilepsia . 1999;40:480-484.
9.
Calandre EP, Rodriquez-Lopez C., Blazquez A., Cano D.Serum lipids, lipoprotein and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital. Acta Neurol Scand. 1991;83:250-253.
10.
De Backer G. , Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis . 2003;171:145-155.
11.
Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation . 2004; 110:227-239.
12.
Walldius G. , Jungner I.Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy . J Intern Med. 2004;255:188-205.
13.
Chan DC, Watts GFApolipoproteins as markers and managers of coronary risk. QJM. 2006;99:277-287.
14.
Chan DC, Barrett PH, Watts GFLipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies. Clin Sci. 2004;107:221-232.
15.
Commission on Classification and Terminology of the International League Against Epilepsy.Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia. 1989;30:389-399.
16.
Aynaci FM, Orhan F., Orem A., et al. Effect of antiepileptic drugs on plasma lipoprotein (a) and other lipid levels in childhood. J Child Neurol. 2001;16:367-369.
17.
Eiris JM, Lojo S., Del Rio MC, et al. Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology. 1995;45:1155-1157.
18.
Reddy MNEffect of anticonvulsant drugs on plasma total cholesterol, high-density lipoprotein cholesterol, and apolipoproteins A and B in children with epilepsy . Proc Soc Exp Biol Med. 1985;180:359-363.
19.
Luoma PV, Myllyla VV, Hokkanen E.Relationship between plasma high density lipoprotein cholesterol and anticonvulsant levels in epileptics. J Cardiovasc Pharmacol . 1982;4:1024-1027.
20.
Nikolaos T., Stylianos G., Chryssoula N., et al. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy . Med Sci Monit.2004;10:MT50-MT52.
21.
Franzoni E. , Govoni M., D'addato S., et al. Total cholesterol, high density lipoprotein cholesterol and triglycerides in children receiving antiepileptic drugs. Epilepsia. 1992;33:932-935.
22.
Sozuer DT, Atakil D., Dogu O., et al. Serum lipids in epileptic children treated with carbamazepine and valproate. Eur J Pediatr. 1997;156:565-567.
23.
Verrotti A. , Domizio S., Angelozzi B., et al. Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants . J Paediatr Child Health. 1997;33:242-245.
24.
Mikkonen K. , Knip M., Pakarinen AJ, et al. Growth and lipid metabolism in girls and young women with epilepsy during pubertal maturation. Epilepsia. 2005;46:1114-1120.
25.
Yilmaz E., Dosan Y., Gurgoze MK, Gungor S.Serum lipid changes during anticonvulsive treatment in epileptic children . Acta Neurol Belg. 2001;101:217-220.
26.
Aggarwal A. , Kumar M., Faridi MMEffects of carbamazepine on serum lipids and liver function tests. Indian pediatr. 2005 ; 42:913-918.
27.
Eiris J., Novo-Rodriguez MI, Del Rio M., et al. The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy . Epilepsy Res. 2000;41:1-7.
28.
Mahmoudian T., Iranpour R., Messri N.Serum lipid levels during carbamazepine therapy in epileptic children. Epilepsy Behav . 2005 ;6:257-259.
29.
Zeitlhofer J., Doppelbauer A., Tribl G., et al. Changes of serum lipid patterns during long-term anticonvulsive treatment. Clin Investig. 1993;71:574-578.
30.
Dada G., Caksen H., Içaasiolu D.Effect of long term carbamazepine therapy on serum lipids, vitamin B12 and folic acid level in children. J Pediatr Endocrinol Metab. 2003;16:193-196.
31.
Sonmez FM, Demir E., Orem A., et al. Effect of antiepileptic drugs on plasma lipids, lipoprotein(a) and liver enzymes. J Child Neurol. 2006;21:70-74.
32.
Tekgul H., Demir N., Gokben S.Serum lipid profile in children receiving anti-epileptic drug monotherapy: is it atherogenic? J Pediatr Endocrinol Metab. 2006;19:1151-1155.
33.
de Juan Frigola J., Crespo Hernández M., Braga Hernández S.The effects of phenobarbital, valproic acid and carbamazepine on the serum lipids and lipoproteins in a pediatric population. An Esp Pediatr. 1996;44:133-138.
34.
Verrotti A. , Basciani F., Domizio S., et al. Serum lipids and lipoproteins in patients treated with antiepileptic drugs. Pediatr Neurol. 1998;19:364-367.
35.
Kuhara-Baillie TA, Rettenmeier AWValproate biotransformation. In: Levy RH, Dreifuss FE , Mattson RH, Meldrum BS, Penry JK , eds. Antiepileptic Drugs. New York, NY: Raven Press; 1989:6014.
36.
Rifai N., Bachorik S., Albers J.Lipids, lipoproteins, and apolipoproteins. In: Burlis AC, Ashwood RE, eds. Tietz Textbook of Clinical Biochemistry. Philadelphia, PA: WB Saunders Company;1999: 809-860.
37.
Radunovic N. , Kuczynski E., Rosen T., et al. Plasma apolipoprotein A-I and B concentrations in growth-retarded fetuses: a link between low birth weight and adult atherosclerosis . J Clin Endocrinol Metab . 2000;85:85-88.
